The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
From MaRDI portal
Publication:5427414
DOI10.1111/j.1541-0420.2006.00666.xzbMath1124.62084OpenAlexW2015506353WikidataQ51916813 ScholiaQ51916813MaRDI QIDQ5427414
No author found.
Publication date: 20 November 2007
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.1541-0420.2006.00666.x
Related Items
A system for determining maximum tolerated dose in clinical trial ⋮ A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents ⋮ Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials ⋮ gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials ⋮ Generalized Bayes Quantification Learning under Dataset Shift ⋮ Bayesian phase I/II adaptively randomized oncology trials with combined drugs ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Continual reassessment method with multiple toxicity constraints ⋮ On the consistency of the continual reassessment method with multiple toxicity constraints ⋮ Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials ⋮ Risk-Group-Specific Dose Finding Based on an Average Toxicity Score ⋮ Simple benchmark for complex dose finding studies ⋮ Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
Cites Work
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Curve-Free and Model-Based Continual Reassessment Method Designs
- Design and Analysis of Phase I Clinical Trials
- Pseudo Maximum Likelihood Methods: Theory
- Continual Reassessment Method: A Likelihood Approach
- Semiparametric regression for count data
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
